RESUMEN
Compared with conventional coagulation tests and factor-specific assays, viscoelastic hemostatic assays (VHAs) can provide a more thorough evaluation of clot formation and lysis but have several limitations including clot deformation. In this proof-of-concept study, we test a noncontact technique, termed resonant acoustic rheometry (RAR), for measuring the kinetics of human plasma coagulation. Specifically, RAR utilizes a dual-mode ultrasound technique to induce and detect surface oscillation of blood samples without direct physical contact and measures the resonant frequency of the surface oscillation over time, which is reflective of the viscoelasticity of the sample. Analysis of RAR results of normal plasma allowed defining a set of parameters for quantifying coagulation. RAR detected a flat-line tracing of resonant frequency in hemophilia A plasma that was corrected with the addition of tissue factor. Our RAR results captured the kinetics of plasma coagulation and the newly defined RAR parameters correlated with increasing tissue factor concentration in both healthy and hemophilia A plasma. These findings demonstrate the feasibility of RAR as a novel approach for VHA, providing the foundation for future studies to compare RAR parameters to conventional coagulation tests, factor-specific assays, and VHA parameters.
Asunto(s)
Hemofilia A , Humanos , Tromboplastina , Cinética , Coagulación Sanguínea , Pruebas de Coagulación Sanguínea/métodos , AcústicaRESUMEN
In this study, we show that replication-competent subgenomic hepatitis C virus (HCV) RNA can be transferred to permissive Huh7 cells, leading to the establishment of viral RNA replication. Further, we show that these events are mediated by exosomes rather than infectious virus particles. If similar events occur in vivo, this could represent a novel, albeit inefficient, mechanism of viral spread and immune escape.
Asunto(s)
Exosomas/metabolismo , Hepacivirus/fisiología , Hepatocitos/virología , ARN Viral/metabolismo , Replicación Viral , Transporte Biológico , Línea Celular , Hepacivirus/genética , HumanosRESUMEN
Viral nucleic acids often trigger an innate immune response in infected cells. Many viruses, including hepatitis C virus (HCV), have evolved mechanisms to evade intracellular recognition. Nevertheless, HCV-permissive cells can trigger a viral RNA-, TLR7-, and cell-contact-dependent compensatory interferon response in nonpermissive plasmacytoid dendritic cells (pDCs). Here we report that these events are mediated by transfer of HCV-RNA-containing exosomes from infected cells to pDCs. The exosomal viral RNA transfer is dependent on the endosomal sorting complex required for transport (ESCRT) machinery and on Annexin A2, an RNA-binding protein involved in membrane vesicle trafficking, and is suppressed by exosome release inhibitors. Further, purified concentrated HCV-RNA-containing exosomes are sufficient to activate pDCs. Thus, vesicular sequestration and exosomal export of viral RNA may serve both as a viral strategy to evade pathogen sensing within infected cells and as a host strategy to induce an unopposed innate response in replication-nonpermissive bystander cells.
Asunto(s)
Células Dendríticas/inmunología , Células Dendríticas/metabolismo , Exosomas/metabolismo , Hepacivirus/inmunología , Inmunidad Innata , ARN Viral/inmunología , ARN Viral/metabolismo , Células Cultivadas , Células Dendríticas/virología , Exosomas/virología , Hepatocitos/virología , HumanosRESUMEN
Stress granules (SGs) are cytoplasmic structures that are induced in response to environmental stress, including viral infections. Here we report that hepatitis C virus (HCV) triggers the appearance of SGs in a PKR- and interferon (IFN)-dependent manner. Moreover, we show an inverse correlation between the presence of stress granules and the induction of IFN-stimulated proteins, i.e., MxA and USP18, in HCV-infected cells despite high-level expression of the corresponding MxA and USP18 mRNAs, suggesting that interferon-stimulated gene translation is inhibited in stress granule-containing HCV-infected cells. Finally, in short hairpin RNA (shRNA) knockdown experiments, we found that the stress granule proteins T-cell-restricted intracellular antigen 1 (TIA-1), TIA1-related protein (TIAR), and RasGAP-SH3 domain binding protein 1 (G3BP1) are required for efficient HCV RNA and protein accumulation at early time points in the infection and that G3BP1 and TIA-1 are required for intracellular and extracellular infectious virus production late in the infection, suggesting that they are required for virus assembly. In contrast, TIAR downregulation decreases extracellular infectious virus titers with little effect on intracellular RNA content or infectivity late in the infection, suggesting that it is required for infectious particle release. Collectively, these results illustrate that HCV exploits the stress granule machinery at least two ways: by inducing the formation of SGs by triggering PKR phosphorylation, thereby downregulating the translation of antiviral interferon-stimulated genes, and by co-opting SG proteins for its replication, assembly, and egress.
Asunto(s)
Gránulos Citoplasmáticos/metabolismo , Hepacivirus/fisiología , Interferón beta/metabolismo , ARN Viral/biosíntesis , Proteínas de Unión al ARN/metabolismo , Ensamble de Virus , Liberación del Virus , eIF-2 Quinasa/metabolismo , Proteínas Portadoras/metabolismo , Línea Celular , Línea Celular Tumoral , ADN Helicasas , Regulación hacia Abajo , Endopeptidasas/biosíntesis , Endopeptidasas/genética , Proteínas de Unión al GTP/biosíntesis , Proteínas de Unión al GTP/genética , Células HEK293 , Hepacivirus/genética , Hepacivirus/inmunología , Humanos , Interferón beta/farmacología , Proteínas de Resistencia a Mixovirus , Proteínas de Unión a Poli(A)/metabolismo , Proteínas de Unión a Poli-ADP-Ribosa , Biosíntesis de Proteínas , ARN Helicasas , Interferencia de ARN , Proteínas con Motivos de Reconocimiento de ARN , ARN Mensajero/biosíntesis , ARN Interferente Pequeño , ARN Viral/genética , Proteínas de Unión al ARN/genética , Antígeno Intracelular 1 de las Células T , Ubiquitina Tiolesterasa , Replicación Viral/efectos de los fármacos , eIF-2 Quinasa/genéticaRESUMEN
We analyzed the biochemical and ultrastructural properties of hepatitis C virus (HCV) particles produced in cell culture. Negative-stain electron microscopy revealed that the particles were spherical (â¼40- to 75-nm diameter) and pleomorphic and that some of them contain HCV E2 protein and apolipoprotein E on their surfaces. Electron cryomicroscopy revealed two major particle populations of â¼60 and â¼45 nm in diameter. The â¼60-nm particles were characterized by a membrane bilayer (presumably an envelope) that is spatially separated from an internal structure (presumably a capsid), and they were enriched in fractions that displayed a high infectivity-to-HCV RNA ratio. The â¼45-nm particles lacked a membrane bilayer and displayed a higher buoyant density and a lower infectivity-to-HCV RNA ratio. We also observed a minor population of very-low-density, >100-nm-diameter vesicular particles that resemble exosomes. This study provides low-resolution ultrastructural information of particle populations displaying differential biophysical properties and specific infectivity. Correlative analysis of the abundance of the different particle populations with infectivity, HCV RNA, and viral antigens suggests that infectious particles are likely to be present in the large â¼60-nm HCV particle populations displaying a visible bilayer. Our study constitutes an initial approach toward understanding the structural characteristics of infectious HCV particles.
Asunto(s)
Hepacivirus/ultraestructura , Virión/ultraestructura , Antígenos Virales/análisis , Cápside , Técnicas de Cultivo de Célula , Hepacivirus/patogenicidad , Membrana Dobles de Lípidos , Microscopía Electrónica , Tamaño de la Partícula , ARN Viral/análisis , Virión/patogenicidadRESUMEN
Inhibition of hepatitis B virus (HBV) replication and viral clearance from an infected host requires both the innate and adaptive immune responses. Expression of interferon (IFN)-inducible proteasome catalytic and regulatory subunits correlates with the IFN-alpha/beta- and IFN-gamma-mediated noncytopathic inhibition of HBV in transgenic mice and hepatocytes, as well as with clearance of the virus in acutely infected chimpanzees. The immunoproteasome catalytic subunits LMP2 and LMP7 alter proteasome specificity and influence the pool of peptides available for presentation by major histocompatibility complex class I molecules. We found that these subunits influenced both the magnitude and specificity of the CD8 T-cell response to the HBV polymerase and envelope proteins in immunized HLA-A2-transgenic mice. We also examined the role of LMP2 and LMP7 in the IFN-alpha/beta- and IFN-gamma-mediated inhibition of virus replication using HBV transgenic mice and found that they do not play a direct role in this process. These results demonstrate the ability of the IFN-induced proteasome catalytic subunits to shape the HBV-specific CD8 T-cell response and thus potentially influence the progression of infection to acute or chronic disease. In addition, these studies identify a potential key role for IFN in regulating the adaptive immune response to HBV through alterations in viral antigen processing.
Asunto(s)
Cisteína Endopeptidasas/metabolismo , Productos del Gen env/metabolismo , Productos del Gen pol/metabolismo , Virus de la Hepatitis B/patogenicidad , Hepatitis B/inmunología , Interferones/farmacología , Complejos Multienzimáticos/metabolismo , Animales , Linfocitos T CD8-positivos/inmunología , Cisteína Endopeptidasas/genética , Productos del Gen env/inmunología , Productos del Gen pol/inmunología , Antígeno HLA-A2/metabolismo , Células HeLa , Hepatitis B/fisiopatología , Hepatitis B/prevención & control , Hepatitis B/virología , Virus de la Hepatitis B/genética , Virus de la Hepatitis B/inmunología , Virus de la Hepatitis B/metabolismo , Humanos , Inmunización , Interferón gamma/inmunología , Interferón gamma/metabolismo , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Ratones Transgénicos , Complejos Multienzimáticos/genética , Complejo de la Endopetidasa Proteasomal , Replicación ViralRESUMEN
We have previously shown that IFN-beta inhibits hepatitis B virus (HBV) replication by noncytolytic mechanisms that either destabilize pregenomic (pg)RNA-containing capsids or prevent their assembly. Using immortalized murine hepatocyte cell lines stably transfected with a doxycycline (dox)-inducible HBV replication system, we now show that replication-competent pgRNA-containing capsids are not produced when the cells are pretreated with IFN-beta before HBV expression is induced with dox. Furthermore, the turnover rate of preformed HBV RNA-containing capsids is not changed in the presence of IFN-beta or IFN-gamma under conditions in which further pgRNA synthesis is inhibited by dox removal. In summary, these results demonstrate that types 1 and 2 IFN activate hepatocellular mechanism(s) that prevent the formation of replication-competent HBV capsids and, thereby, inhibit HBV replication.
Asunto(s)
Cápside/efectos de los fármacos , Virus de la Hepatitis B/metabolismo , Interferón beta/farmacología , ARN/metabolismo , Replicación Viral/efectos de los fármacos , Animales , Southern Blotting , Línea Celular , Doxiciclina , Ratones , Plásmidos/genética , Reacción en Cadena de la PolimerasaRESUMEN
Lambda interferon (IFN-lambda) induces an intracellular IFN-alpha/beta-like antiviral response through a receptor complex distinct from the IFN-alpha/beta receptor. We therefore determined the ability of IFN-lambda to inhibit hepatitis B virus (HBV) and hepatitis C virus (HCV) replication. IFN-lambda inhibits HBV replication in a differentiated murine hepatocyte cell line with kinetics and efficiency similar to IFN-alpha/beta and does not require the expression of IFN-alpha/beta or IFN-gamma. Furthermore, IFN-lambda blocked the replication of a subgenomic and a full-length genomic HCV replicon in human hepatocyte Huh7 cells. These results suggest the possibility that IFN-lambda may be therapeutically useful in the treatment of chronic HBV or HCV infection.
Asunto(s)
Hepacivirus/fisiología , Virus de la Hepatitis B/fisiología , Interferones/farmacología , Replicación Viral/efectos de los fármacos , Animales , Antivirales/farmacología , Células Cultivadas , Hepacivirus/efectos de los fármacos , Virus de la Hepatitis B/efectos de los fármacos , Humanos , RatonesRESUMEN
Hepatitis B virus (HBV) causes acute and chronic hepatitis and hepatocellular carcinoma. Although a preventive vaccine is available, the therapeutic options for chronically infected patients are limited. It has been shown that RNA interference can prevent HBV gene expression and replication in vivo when HBV expression vectors are delivered simultaneously with small interfering RNA (siRNA) or siRNA expression constructs. However, the therapeutic potential of siRNAs to interrupt ongoing HBV replication in vivo has not been established. Here, we show that expression of HBV-specific siRNAs in the liver of HBV transgenic mice by recombinant adenoviruses can suppress preexisting HBV gene expression and replication to almost undetectable levels for at least 26 days. These results demonstrate that efficiently delivered siRNAs should be able to silence HBV in chronically infected patients.
Asunto(s)
Virus de la Hepatitis B/efectos de los fármacos , Hepatitis B/tratamiento farmacológico , Hepatitis Crónica/tratamiento farmacológico , Hígado/virología , ARN Interferente Pequeño/uso terapéutico , Adenoviridae/genética , Animales , Enfermedad Crónica , Vectores Genéticos , Hepatitis B/complicaciones , Virus de la Hepatitis B/genética , Hepatitis Crónica/virología , Ratones , Ratones Transgénicos , ARN Interferente Pequeño/administración & dosificación , ARN Interferente Pequeño/farmacología , ARN Viral/efectos de los fármacos , Tiempo , Replicación Viral/efectos de los fármacosRESUMEN
The replication of hepatitis B virus (HBV) in hepatocytes is strongly inhibited in response to IFN-alpha/beta and IFN-gamma. Although it has been previously demonstrated that IFN-alpha/beta eliminates HBV RNA-containing capsids from the cell in a proteasome-dependent manner, the precise cellular pathway that mediates this antiviral effect has not been identified. Because IFN-induced signal transduction involves kinase-mediated activation of gene expression, we used an immortalized hepatocyte cell line that replicates HBV in an IFN-sensitive manner to investigate the role of cellular kinase activity and the cellular transcription and translation machinery in the antiviral effect. Our results indicate that Janus kinase activity is required for the antiviral effect of IFN against HBV, but that phosphatidylinositol 3-kinase, cyclin-dependent kinase, mitogen-activated protein kinase, and NF-kappaB activity are not. Additionally, we found that inhibitors of cellular transcription and translation completely abolish the antiviral effect, which also appears to require cellular kinase activity downstream of signal transduction and gene expression. Collectively, these results identify IFN-regulated pathways that interrupt the HBV replication cycle by eliminating viral RNA-containing capsids from the cell, and they provide direction for discovery of the terminal effector molecules that ultimately mediate this antiviral effect.